Shingrix (Zostavax) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing awareness of shingles complications, aging global population growth, prior limitations of live attenuated vaccines, expansion of immunization guidelines for older adults, increasing physician recommendation rates.

The growth in the forecast period can be attributed to increasing adult vaccination coverage targets, rising healthcare spending on preventive care, expansion of recombinant vaccine pipelines, growing government-supported immunization initiatives, increasing focus on reducing post-herpetic neuralgia burden. Major trends in the forecast period include increasing adoption of recombinant vaccine platforms, rising focus on adult immunization programs, growing demand for long-lasting shingles protection, expansion of cold-chain optimized vaccine distribution, enhanced emphasis on vaccine safety and efficacy.

The increasing adoption of vaccination is expected to drive the growth of the Shingrix (Zostavax) market moving forward. Vaccination is the process of administering a vaccine to stimulate the body's immune system to recognize and fight specific pathogens. The growing adoption of vaccination is driven by increased awareness of its effectiveness in preventing diseases, reducing disease burden, and the development of safe, accessible vaccines. Public health campaigns, improved healthcare infrastructure, and global vaccination initiatives also contribute to the widespread acceptance of vaccines. Shingrix (Zostavax) plays a significant role in vaccination by offering effective protection against shingles and its complications, particularly for adults over 50, and significantly reducing the risk of shingles recurrence and post-herpetic neuralgia. For example, in May 2024, a study published by the Journal of the American Medical Association (JAMA), a U.S.-based peer-reviewed medical journal, found that shingles vaccinations covered by Medicare Part D increased by 46% in the year following the IRA policy’s implementation in January 2023. Thus, the growing adoption of vaccination is expected to drive the continued growth of the Shingrix (Zostavax) market.

Major companies in the Shingrix (Zostavax) market are focusing on developing innovative solutions, such as non-live, recombinant subunit adjuvanted vaccines, to meet the rising demand for safer and more effective immunization, particularly for individuals with age-related immune decline and those in immunocompromised populations. A non-live, recombinant subunit adjuvanted vaccine contains specific protein components (antigens) of a pathogen, combined with an adjuvant to enhance the immune response, in contrast to traditional live-attenuated vaccines that use weakened forms of the whole virus. For instance, in 2023, GSK plc, a UK-based biopharmaceutical company, launched Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, administered intramuscularly in two doses, and includes the glycoprotein E antigen along with GSK’s proprietary AS01B adjuvant system. Shingrix stimulates a robust and long-lasting immune response, overcoming immune decline in older adults, and offers high efficacy (up to ~97%).

In October 2023, Chongqing Zhifei, a China-based biotechnology company specializing in the development, manufacturing, and distribution of vaccines, partnered with GSK plc. This collaboration aims to expand the market reach of Shingrix, GSK’s top-selling shingles vaccine, in China, the world’s second-largest pharmaceutical market by spending.

Major companies operating in the shingrix (zostavax) market are GSK plc.

North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the shingrix (zostavax) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the shingrix and zostavax market by increasing costs of imported biologic raw materials, adjuvants, packaging components, and cold-chain logistics equipment required for vaccine production and distribution. Manufacturing and supply chains in North America and Europe are most affected due to dependence on globally sourced biologics inputs, while Asia-Pacific faces higher distribution and storage costs. These tariffs are contributing to increased vaccine procurement expenses and pricing pressures for public health programs. However, they are also encouraging regional vaccine manufacturing, localized fill-finish operations, and long-term investments in domestic biologics supply resilience.

The shingrix (zostavax) market research report is one of a series of new reports that provides shingrix (zostavax) market statistics, including shingrix (zostavax) industry global market size, regional shares, competitors with a shingrix (zostavax) market share, detailed shingrix (zostavax) market segments, market trends and opportunities, and any further data you may need to thrive in the shingrix (zostavax) industry. This shingrix (zostavax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is primarily used to immunize adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications.

The main formulations of Shingrix (Zostavax) include recombinant vaccines (Shingrix) and live-attenuated vaccines (Zostavax). The recombinant vaccine (Shingrix) is a non-live vaccine developed using recombinant DNA technology. It works by introducing a protein from the varicella-zoster virus to stimulate the immune system, providing strong protection against shingles. The indications for Shingrix include shingles prevention and post-herpetic neuralgia, and it is distributed through various channels such as hospital pharmacies and retail pharmacies.

The shingrix (zostavax) market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.